[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07260799":3,"trial-entities:NCT07260799":69,"trial-summary:NCT07260799":73},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":16,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":31,"secondary_outcomes":35,"sex":36,"minimum_age":37,"maximum_age":38,"healthy_volunteers":39,"eligibility_criteria":40,"std_ages":44,"locations":47,"central_contacts":65,"overall_officials":66,"references":67,"see_also_links":68},"NCT07260799","T23-03","Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer","ACTIVE_NOT_RECRUITING","2026-10-31","2026-07","2026-07-20","2025-10-25","Tasso Inc.","INDUSTRY",false,"The purpose of this single-visit study is to demonstrate the performance of capillary blood samples collected with the Tasso+ Serum Gel Capillary Blood Collection System compared to venous reference samples for downstream analyte testing at a clinical laboratory.",null,[18],"Serum Analytes",[],"OBSERVATIONAL",[],{"count":23,"type":24},150,"ESTIMATED",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30},"DIAGNOSTIC_TEST","Tasso+ Serum Gel Capillary Blood Collection System","Clinical evaluation of capillary blood samples collected using the Tasso+ Serum Gel Capillary Blood Collection System for downstream analyte testing.",[28],[32],{"measure":33,"timeFrame":34},"Number participants for which there is statistical equivalence between serum biomarker results obtained from capillary blood vs. venous blood","48 Hours",[],"ALL","18 Years","85 Years",true,{"inclusion":41,"exclusion":42,"raw_text":43},[],[],"Inclusion Criteria:\n\n1. Adults aged 18-85 years with no previous experience with the Tasso+ lancet\n2. Willing and able to provide written informed consent prior to study entry\n3. Willing and able to adhere to study assessments, schedule, prohibitions and restrictions as described in the protocol\n4. Healthy individuals or patients with abnormal analyte values (verified or likely to be) within intended clinical reference ranges as indicated by standard of care testing and\u002For past medical history, in the judgement of the investigator\n\nExclusion Criteria:\n\n1. Present with abnormal skin integrity or atypical skin health near\u002Fon arm collection sites\n2. Mental or physical impairment which would preclude participation in the judgement of the investigator or qualified designee\n3. Trained clinical laboratory and healthcare personnel who have worked in the field in the previous 5 years\n4. Any condition which, in the opinion of the investigator or delegate, makes the participant unsuitable for this study (including, but not limited to, any mental or physical impairment which would preclude provision of adequate and knowledgeable consent)",[45,46],"ADULT","OLDER_ADULT",[48,57],{"facility":49,"city":50,"state":51,"zip":52,"country":53,"geoPoint":54},"Celesta \u002F American Research Labs","Atlantis","Florida","33462","United States",{"lat":55,"lon":56},26.5909,-80.10088,{"facility":58,"city":59,"state":60,"zip":61,"country":53,"geoPoint":62},"Tasso, Inc.","Seattle","Washington","98119",{"lat":63,"lon":64},47.60621,-122.33207,[],[],[],[],{"nct_id":4,"conditions":70,"biomarkers":72},[71],"Healthy",[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]